Targets of functional imaging

Metabolism
Perfusion (blood flow)
Neurotransmitter systems
Infection and inflammation
Protein deposits proteinopathies)
Organs and tissues


References:

Alam IS, Arshad MA, Nguyen Q, Aboagye EO. Radiopharmaceuticals as probes to characterize tumour tissue. Eur J Nucl Med Mol Imaging 2015; 42: 537-561. doi: 10.1007/s00259-014-2984-3.

Cumming P, Vasdev N. The assay of enzyme activity by positron emission tomography. Neuromethods 2012; 71: 111-135. doi: 10.1007/7657_2012_53.

Holland JP, Cumming P, Vasdev N. PET radiopharmaceuticals for probing enzymes in the brain. Am J Nucl Med Mol Imaging 2013; 3(3): 194-216. PMID: 23638333.

Neumann K, Flavell R, Wilson DM. Exploring metabolism in vivo using endogenous 11C metabolic tracers. Semin Nucl Med. 2017; 47: 461-473. doi: 10.1053/j.semnuclmed.2017.05.003.

Sosuke Miyoshi, Keisuke Mitsuoka, Shintaro Nishimura and Stephan A. Veltkamp (2011). Radioisotopes in Drug Research and Development: Focus on Positron Emission Tomography, Radioisotopes - Applications in Bio-Medical Science, Prof. Nirmal Singh (Ed.), ISBN: 978-953-307-748-2, InTech, doi: 10.5772/22728.

Vāvere AL, Scott PJH. Clinical applications of small-molecule PET radiotracers: current progress and future outlook. Semin Nucl Med. 2017; 47: 429-453. doi: 10.1053/j.semnuclmed.2017.05.001.

Wong DF, Gründer G, Brasic JR. Brain imaging research: Does the science serve clinical practice? Int Rev Psychiatry 2007; 19(5): 541-558. PMID: 17896234.



Tags: ,


Updated at: 2019-03-07
Created at: 2007-10-22
Written by: Vesa Oikonen